Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Benitec Biopharma’s gene-silencing breakthroughs inside a 10-K or 8-K can feel like wading through lab notebooks. Clinical timelines, ddRNAi patent tables, and R&D expenses sprawl over hundreds of pages, while Benitec Biopharma insider trading Form 4 transactions surface at unpredictable hours. Stock Titan answers the problem by pairing real-time EDGAR feeds with AI that translates biotech jargon into plain language you can act on.
Need the next cash-runway update? Our platform flags it the moment a Benitec Biopharma quarterly earnings report 10-Q filing drops. Curious whether executives are adding shares before a BB-301 trial read-out? Receive instant alerts on Benitec Biopharma Form 4 insider transactions real-time. Each document arrives with an AI-powered summary that highlights pipeline milestones, licensing revenue, and risk factors—Benitec Biopharma SEC filings explained simply.
Explore every filing type in one place:
- 10-K: R&D spend, patent life, and Benitec Biopharma annual report 10-K simplified
- 10-Q: quarter-over-quarter trial costs and Benitec Biopharma earnings report filing analysis
- 8-K: clinical data releases with Benitec Biopharma 8-K material events explained
- DEF 14A: Benitec Biopharma proxy statement executive compensation decoded
- Form 4: Benitec Biopharma executive stock transactions Form 4 tracked to the minute
Whether you’re benchmarking cash burn or understanding Benitec Biopharma SEC documents with AI, Stock Titan condenses complexity into clear insights, so you spend time on decisions, not documentation.
Benitec Biopharma Inc. (BNTC) will hold its 2025 Annual Meeting virtually on December 1, 2025 at 1:00 p.m. PT. Stockholders of record at the close of business on October 10, 2025 may vote. As of the record date, 26,250,469 shares of common stock were outstanding. Holders will vote on three items: (1) elect two Class III directors (Dr. Jerel Banks and Megan Boston), (2) ratify Baker Tilly US, LLP as auditor for fiscal year ending June 30, 2026, and (3) approve a non-binding say‑on‑pay advisory vote.
The company will conduct the meeting at www.meetnow.global/M4KC5WC, with voting also available via www.investorvote.com/BNTC. The outstanding count excludes unexercised pre‑funded warrants for up to 15,270,806 shares, which carry no voting rights until exercised. The proxy details quorum and vote standards, committee composition, and director independence. Principal holders include entities affiliated with Suvretta Capital at 49.9%. The proxy also discloses a March 2025 financing with gross proceeds of $30.5 million and net proceeds of $28.2 million, and reports auditor fees of $666,290 for fiscal 2025.
Benitec Biopharma Inc. (BNTC) has filed a Form S-3 shelf registration to enable sales of common stock, debt securities, warrants and units. The prospectus references a February 2024 S-3 Shelf and a November 2024 S-3 Shelf; as of the filing, $94,541,030 of securities registered under the November 2024 S-3 Shelf remain unsold and are included in this new registration statement. The company describes BB-301, an AAV-based gene therapy using a "silence and replace" approach for OPMD, and notes that BB-301 has Orphan Drug Designation in the U.S. and EU. The prospectus incorporates by reference the companys Form 10-K for the year ended June 30, 2025, and warns investors to review the risk factors disclosed in that Annual Report and subsequent SEC filings.
Benitec Biopharma Inc. (BNTC) is an early-stage genetic medicines company developing BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug Designation in the United States and the European Union and is in a Phase 1b/2a single-arm, open-label, sequential dose-escalation study (NCT06185673) with dosing delivered directly to pharyngeal muscles and interim safety/efficacy readouts expected at 180-day intervals.
Financially, the company reported $97.7 million in cash and cash equivalents as of June 30, 2025, used cash in operations of $23.6 million for the year, and raised material proceeds during the year (including a $40.0 million PIPE and additional offerings), with total net proceeds from issuances and warrant exercises during the fiscal year stated at $70.5 million. The company disclosed a restatement related to prior-period recognition of certain non-cash share-based compensation expenses and notes it will continue to incur operating losses and depend on financing to fund operations.
Janus Henderson Group plc and its affiliate Janus Henderson Biotech Innovation Master Fund Ltd report beneficial ownership stakes in Benitec Biopharma Inc. Janus Henderson Group is reported to beneficially own 2,902,794 shares, equal to 11.3% of the common stock, with shared voting and shared dispositive power over those shares. The Biotech Innovation Master Fund is reported to beneficially own 2,193,481 shares, equal to 8.6% of the common stock, also held with shared voting and dispositive power.
The filing includes an explicit certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The filing identifies the reporting persons as an investment adviser/holding company and an investment vehicle.
Janus Henderson Group plc and an affiliated fund report beneficial holdings in Benitec Biopharma Inc. common stock (CUSIP 08205P209). The filing shows Janus Henderson Group plc with 25,600,210 shares of shared voting and dispositive power, representing 11.3% of the class. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 2,193,481 shares (shared voting and dispositive power), representing 8.6%. The schedule includes a certification that the securities were acquired in the ordinary course of business and a power of attorney executed by Janus Henderson Group plc authorizing named attorneys-in-fact to file required ownership reports.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
